tetano
Editor, Senior Moderator
Sci Rep
. 2023 Jun 28;13(1):10501.
doi: 10.1038/s41598-023-37405-5. Generation of potentially inhibitory autoantibodies to ADAMTS13 in coronavirus disease 2019
Adrian A N Doevelaar[SUP] 1 [/SUP], Martin Bachmann[SUP] 2 [/SUP], Bodo Hölzer[SUP] 1 [/SUP], Felix S Seibert[SUP] 1 [/SUP], Benjamin J Rohn[SUP] 1 [/SUP], Panagiota Zgoura[SUP] 1 [/SUP], Oliver Witzke[SUP] 3 [/SUP], Ulf Dittmer[SUP] 4 [/SUP], Thorsten Brenner[SUP] 5 [/SUP], Krystallenia Paniskaki[SUP] 3 6 [/SUP], Serap Yilmaz[SUP] 2 [/SUP], Rita Dittmer[SUP] 7 [/SUP], Sonja Schneppenheim[SUP] 7 [/SUP], Jochen Wilhelm[SUP] 7 [/SUP], Ulrik Stervbo[SUP] 6 [/SUP], Nina Babel[SUP] 6 [/SUP], Ulrich Budde[SUP] #[/SUP][SUP] 7 [/SUP], Timm H Westhoff[SUP] #[/SUP][SUP] 8 [/SUP]
Affiliations
It has recently been shown that von Willebrand factor (VWF) multimers contribute to immunothrombosis in Coronavirus disease 2019 (COVID-19). Since COVID-19 is associated with an increased risk of autoreactivity, the present study investigates, whether the generation of autoantibodies to ADAMTS13 contributes to this finding. In this observational prospective controlled multicenter study blood samples and clinical data of patients hospitalized for COVID-19 were collected from April to November 2020. The study included 156 individuals with 90 patients having confirmed COVID-19 of mild to critical severity. 30 healthy individuals and 36 critically ill ICU patients without COVID-19 served as controls. ADAMTS13 antibodies occurred in 31 (34.4%) COVID-19 patients. Antibodies occurred more often in critically ill COVID-19 patients (55.9%) than non-COVID-19 ICU patients and healthy controls (5.6% and 6.7%; p < 0.001), respectively. Generation of ADAMTS13 antibodies in COVID-19 was associated with lower ADAMTS13 activity (56.5%, interquartile range (IQR) 21.25 vs. 71.5%, IQR 24.25, p = 0.0041), increased disease severity (severe or critical in 90% vs. 62.3%, p = 0.019), and a trend to higher mortality (35.5% vs. 18.6%, p = 0.077). Median time to antibody development was 11 days after first positive SARS-CoV-2-PCR specimen. Gel analysis of VWF multimers resembled the constellation in patients with TTP. The present study demonstrates for the first time, that generation of ADAMTS13 antibodies is frequent in COVID-19, associated with lower ADAMTS13 activity and increased risk of an adverse disease course. These findings provide a rationale to include ADAMTS13 antibodies in the diagnostic workup of SARS-CoV-2 infections.
. 2023 Jun 28;13(1):10501.
doi: 10.1038/s41598-023-37405-5. Generation of potentially inhibitory autoantibodies to ADAMTS13 in coronavirus disease 2019
Adrian A N Doevelaar[SUP] 1 [/SUP], Martin Bachmann[SUP] 2 [/SUP], Bodo Hölzer[SUP] 1 [/SUP], Felix S Seibert[SUP] 1 [/SUP], Benjamin J Rohn[SUP] 1 [/SUP], Panagiota Zgoura[SUP] 1 [/SUP], Oliver Witzke[SUP] 3 [/SUP], Ulf Dittmer[SUP] 4 [/SUP], Thorsten Brenner[SUP] 5 [/SUP], Krystallenia Paniskaki[SUP] 3 6 [/SUP], Serap Yilmaz[SUP] 2 [/SUP], Rita Dittmer[SUP] 7 [/SUP], Sonja Schneppenheim[SUP] 7 [/SUP], Jochen Wilhelm[SUP] 7 [/SUP], Ulrik Stervbo[SUP] 6 [/SUP], Nina Babel[SUP] 6 [/SUP], Ulrich Budde[SUP] #[/SUP][SUP] 7 [/SUP], Timm H Westhoff[SUP] #[/SUP][SUP] 8 [/SUP]
Affiliations
- PMID: 37380654
- DOI: 10.1038/s41598-023-37405-5
It has recently been shown that von Willebrand factor (VWF) multimers contribute to immunothrombosis in Coronavirus disease 2019 (COVID-19). Since COVID-19 is associated with an increased risk of autoreactivity, the present study investigates, whether the generation of autoantibodies to ADAMTS13 contributes to this finding. In this observational prospective controlled multicenter study blood samples and clinical data of patients hospitalized for COVID-19 were collected from April to November 2020. The study included 156 individuals with 90 patients having confirmed COVID-19 of mild to critical severity. 30 healthy individuals and 36 critically ill ICU patients without COVID-19 served as controls. ADAMTS13 antibodies occurred in 31 (34.4%) COVID-19 patients. Antibodies occurred more often in critically ill COVID-19 patients (55.9%) than non-COVID-19 ICU patients and healthy controls (5.6% and 6.7%; p < 0.001), respectively. Generation of ADAMTS13 antibodies in COVID-19 was associated with lower ADAMTS13 activity (56.5%, interquartile range (IQR) 21.25 vs. 71.5%, IQR 24.25, p = 0.0041), increased disease severity (severe or critical in 90% vs. 62.3%, p = 0.019), and a trend to higher mortality (35.5% vs. 18.6%, p = 0.077). Median time to antibody development was 11 days after first positive SARS-CoV-2-PCR specimen. Gel analysis of VWF multimers resembled the constellation in patients with TTP. The present study demonstrates for the first time, that generation of ADAMTS13 antibodies is frequent in COVID-19, associated with lower ADAMTS13 activity and increased risk of an adverse disease course. These findings provide a rationale to include ADAMTS13 antibodies in the diagnostic workup of SARS-CoV-2 infections.